A Closer Look at 18 Analyst Recommendations For Eli Lilly and Co
Portfolio Pulse from Benzinga Insights
Eli Lilly and Co (NYSE:LLY) has been evaluated by 18 analysts over the last three months, showing a diverse range of opinions. The average 12-month price target for LLY has increased to $781.94 from $701.64, indicating a bullish sentiment among analysts. Key financial indicators such as market capitalization, revenue growth, net margin, ROE, and ROA highlight Eli Lilly's strong market position and financial performance, despite a high debt-to-equity ratio.
March 01, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly has received positive evaluations from analysts, with an increased average 12-month price target and strong financial performance indicators. This reflects a bullish sentiment and strong market position.
The increase in the average 12-month price target by analysts, combined with Eli Lilly's strong financial performance indicators such as revenue growth, net margin, ROE, and ROA, suggests a bullish sentiment towards the stock. However, the high debt-to-equity ratio introduces a note of caution.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100